Kymera Therapeutics, Inc. (NASDAQ:KYMR - Free Report) - Research analysts at Leerink Partnrs lifted their FY2024 earnings estimates for shares of Kymera Therapeutics in a research note issued to investors on Thursday, October 31st. Leerink Partnrs analyst F. Khurshid now expects that the company will post earnings per share of ($3.04) for the year, up from their prior forecast of ($3.25). Leerink Partnrs has a "Strong-Buy" rating on the stock. The consensus estimate for Kymera Therapeutics' current full-year earnings is ($2.85) per share. Leerink Partnrs also issued estimates for Kymera Therapeutics' Q4 2024 earnings at ($0.94) EPS, Q1 2025 earnings at ($0.99) EPS, Q2 2025 earnings at ($1.00) EPS, Q3 2025 earnings at ($1.04) EPS, Q4 2025 earnings at ($1.15) EPS, FY2025 earnings at ($4.18) EPS and FY2026 earnings at ($4.13) EPS.
Kymera Therapeutics (NASDAQ:KYMR - Get Free Report) last posted its quarterly earnings results on Thursday, October 31st. The company reported ($0.82) earnings per share for the quarter, beating the consensus estimate of ($0.83) by $0.01. Kymera Therapeutics had a negative net margin of 191.26% and a negative return on equity of 28.05%. The firm had revenue of $3.74 million during the quarter, compared to the consensus estimate of $10.34 million. During the same quarter in the previous year, the firm posted ($0.90) earnings per share. The company's revenue was down 20.9% on a year-over-year basis.
KYMR has been the topic of several other research reports. Guggenheim raised their price target on Kymera Therapeutics from $45.00 to $52.00 and gave the company a "buy" rating in a research note on Friday. Oppenheimer raised their target price on shares of Kymera Therapeutics from $52.00 to $56.00 and gave the company an "outperform" rating in a research report on Friday, September 27th. B. Riley upped their price target on shares of Kymera Therapeutics from $31.00 to $36.00 and gave the stock a "neutral" rating in a research report on Tuesday, July 9th. Wolfe Research raised shares of Kymera Therapeutics from a "peer perform" rating to an "outperform" rating and set a $65.00 price objective on the stock in a report on Monday, August 26th. Finally, Morgan Stanley boosted their price objective on shares of Kymera Therapeutics from $34.00 to $45.00 and gave the stock an "equal weight" rating in a research note on Wednesday, August 14th. Four research analysts have rated the stock with a hold rating, nine have assigned a buy rating and one has issued a strong buy rating to the company's stock. Based on data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average target price of $49.15.
Check Out Our Latest Research Report on Kymera Therapeutics
Shares of NASDAQ KYMR opened at $46.47 on Monday. Kymera Therapeutics has a twelve month low of $9.60 and a twelve month high of $53.27. The firm has a market cap of $2.87 billion, a PE ratio of -19.86 and a beta of 2.21. The business has a fifty day simple moving average of $47.04 and a two-hundred day simple moving average of $40.75.
A number of large investors have recently modified their holdings of KYMR. Harbor Capital Advisors Inc. increased its stake in shares of Kymera Therapeutics by 30.0% in the 3rd quarter. Harbor Capital Advisors Inc. now owns 40,303 shares of the company's stock valued at $1,908,000 after purchasing an additional 9,292 shares in the last quarter. Integrated Advisors Network LLC purchased a new stake in shares of Kymera Therapeutics in the third quarter valued at approximately $294,000. China Universal Asset Management Co. Ltd. increased its position in shares of Kymera Therapeutics by 72.3% in the third quarter. China Universal Asset Management Co. Ltd. now owns 12,422 shares of the company's stock valued at $588,000 after buying an additional 5,214 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. raised its stake in shares of Kymera Therapeutics by 27.5% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,336 shares of the company's stock worth $114,000 after buying an additional 504 shares during the period. Finally, Values First Advisors Inc. purchased a new position in shares of Kymera Therapeutics during the 3rd quarter valued at approximately $61,000.
In other news, Director Jeffrey W. Albers sold 5,000 shares of the stock in a transaction dated Monday, August 26th. The stock was sold at an average price of $49.10, for a total value of $245,500.00. The sale was disclosed in a document filed with the SEC, which is available through this link. In related news, Director Pamela Esposito sold 13,500 shares of the firm's stock in a transaction dated Tuesday, September 17th. The stock was sold at an average price of $48.28, for a total transaction of $651,780.00. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director Jeffrey W. Albers sold 5,000 shares of the firm's stock in a transaction that occurred on Monday, August 26th. The stock was sold at an average price of $49.10, for a total transaction of $245,500.00. The disclosure for this sale can be found here. 15.82% of the stock is currently owned by insiders.
Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Kymera Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Kymera Therapeutics wasn't on the list.
While Kymera Therapeutics currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.